Amneal Pharmaceuticals Inc [AMRX] stock is trading at $10.36, down -1.80%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AMRX shares have gain 3.50% over the last week, with a monthly amount glided 6.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Amneal Pharmaceuticals Inc [NASDAQ: AMRX] stock has seen the most recent analyst activity on June 06, 2025, when Goldman initiated its Buy rating and assigned the stock a price target of $12. Previously, JP Morgan upgraded its rating to Overweight on February 24, 2025, and elevated its price target to $12. On September 06, 2024, upgrade upgraded it’s rating to Neutral but maintained its price target of $9 on the stock. Goldman upgraded its rating to a Buy and raised its price target to $6.50 on March 08, 2021. Guggenheim upgraded its rating to Buy for this stock on December 14, 2020, but kept the price target unchanged to $5.50. In a note dated December 14, 2020, Barclays upgraded an Overweight rating on this stock and boosted its target price from $4.50 to $6.
Amneal Pharmaceuticals Inc [AMRX] stock has fluctuated between $6.68 and $10.68 over the past year. Currently, Wall Street analysts expect the stock to reach $9.5 within the next 12 months. Amneal Pharmaceuticals Inc [NASDAQ: AMRX] shares were valued at $10.36 at the most recent close of the market. An investor can expect a potential drop of -8.3% based on the average AMRX price forecast.
Analyzing the AMRX fundamentals
Amneal Pharmaceuticals Inc [NASDAQ:AMRX] reported sales of 2.85B for the trailing twelve months, which represents a growth of 3.24%. Gross Profit Margin for this corporation currently stands at 0.38% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.03%, and Net Profit Margin reading is 0.0%. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is -0.03 and Total Capital is 0.16. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -22.94.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.27 points at the first support level, and at 10.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.53, and for the 2nd resistance point, it is at 10.71.
Ratios To Look Out For
For context, Amneal Pharmaceuticals Inc’s Current Ratio is 1.43. In addition, the Quick Ratio stands at 0.88 and the Cash Ratio stands at 0.07. Considering the valuation of this stock, the price to sales ratio is 1.14 and price to earnings (TTM) ratio is 1618.75.
Transactions by insiders
Recent insider trading involved Kiely John, Director, that happened on Aug 27 ’25 when 32000.0 shares were sold. Director, Kiely John completed a deal on Aug 27 ’25 to buy 32000.0 shares. Meanwhile, Executive Vice President Shah Nikita sold 0.11 million shares on Aug 22 ’25.
